SCHEMBL524494

SCHEMBL524494

CCCCCCCCCCCC(O)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 1.00
FFAR1 O14842 2/20 1.00
MAPT P10636 1/20 0.59
LCK P06239 1/20 0.59
PPARD Q03181 1/20 0.59
ZDHHC20 Q5W0Z9 1/20 0.59
ZDHHC2 Q9UIJ5 1/20 0.59
FFAR4 Q5NUL3 1/20 0.55
ACE2 Q9BYF1 1/20 0.55
GRIK1 P39086 1/20 0.50
GRIK2 Q13002 1/20 0.50
S1PR2 O95136 1/20 0.49
S1PR4 O95977 1/20 0.49
S1PR1 P21453 1/20 0.49
S1PR3 Q99500 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6237406 1.00 GPR84 (1.00) GPR84FFAR1MAPTLCKPPARD
SCHEMBL2709599 1.00 GPR84 (1.00) GPR84FFAR1MAPTLCKPPARD
SCHEMBL22842 1.00 GPR84 (1.00) GPR84FFAR1MAPTLCKPPARD
SCHEMBL337352 1.00 GPR84 (1.00) GPR84FFAR1MAPTLCKPPARD
SCHEMBL525700 1.00 GPR84 (1.00) GPR84FFAR1MAPTLCKPPARD
SCHEMBL2933185 1.00 GPR84 (1.00) GPR84FFAR1MAPTLCKPPARD
SCHEMBL525619 1.00 GPR84 (1.00) GPR84FFAR1MAPTLCKPPARD
SCHEMBL4757199 1.00 GPR84 (1.00) GPR84FFAR1MAPTLCKPPARD
SCHEMBL525377 1.00 GPR84 (1.00) GPR84FFAR1MAPTLCKPPARD
SCHEMBL525702 1.00 GPR84 (1.00) GPR84FFAR1MAPTLCKPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113557259-B Biosynthesis of gamma-and delta-lactones using cytochrome P450 enzymes with subterminal hydroxylase activity 科纳根公司 2024-03-08 CN claimed
EP-4139387-A1 ADDITIVE COMPOSITION AND USE THEREOF, CONDENSATION POLYMER COMPOSITION, MOLDING COMPOUND AND MOLDING COMPOUNDS PRODUCED THEREFROM, AND MOLDED PARTS AND USE THEREOF Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2023-03-01 EP claimed
CN-115461396-A Additive composition and use thereof, condensation polymer composition, moulding compound and moulded part produced therefrom and use thereof 弗劳恩霍夫应用研究促进协会 2022-12-09 CN claimed
WO-2021213939-A1 ADDITIVE COMPOSITION AND USE THEREOF, CONDENSATION POLYMER COMPOSITION, MOLDING COMPOUND AND MOLDING COMPOUNDS PRODUCED THEREFROM, AND MOLDED PARTS AND USE THEREOF Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2021-10-28 WO claimed
CN-113557259-A Biosynthetic production of gamma-lactones and delta-lactones using cytochrome P450 enzymes with sub-terminal hydroxylase activity 科纳根公司 2021-10-26 CN claimed
US-11112717-B2 Electrostatic ink compositions and scratch-off structures HP INDIGO B.V. (NL) 2021-09-07 US claimed
US-20050287101-A1 Cosmetic composition comprising at least one semi-crystalline polymer, and at least one ester of dimer diol and of acid STEEL FUNDING, LLC 2005-12-29 US claimed
US-20050287103-A1 Cosmetic composition comprising at least one ester and at least one film-forming polymer L'OREAL S.A. (FR) 2005-12-29 US claimed
US-20040175338-A1 Cosmetic composition containing an ester and a pasty compound L'OREAL (FR) 2004-09-09 US claimed
US-6740731-B2 COMPRISING A HYDROXYCARBOXYLIC ACID-CONTAINING POLYMER WHERE THE POLYMER BIODEGRADES HYDROLYTICALLY DURING STORAGE, USE AND DISPOSAL STAGES IN A CONTROLLED MANNER,THE RATE BEING ACCELERATED DURING DISPOSAL; MICROBIOCIDES CARGILL DOW POLYMERS LLC 2004-05-25 US claimed
US-20020123546-A1 Degradation control of environmentally degradable disposable materials ECOPOL, LLC 2002-09-05 US claimed
EP-1044278-A1 BIOSYNTHESIS OF MEDIUM CHAIN LENGTH POLYHYDROXYALKANOATES MONSANTO COMPANY (US) 2000-10-18 EP claimed
US-6008169-A Refrigerator oil composition comprising saturated hydroxy fatty acids and derivatives thereof IDEMITSU KOSAN CO., LTD. (JP) 1999-12-28 US claimed
WO-1999035278-A1 BIOSYNTHESIS OF MEDIUM CHAIN LENGTH POLYHYDROXYALKANOATES MONSANTO COMPANY (US) 1999-07-15 WO claimed
EP-0662107-A4 DEGRADATION CONTROL OF ENVIRONMENTALLY DEGRADABLE DISPOSABLE MATERIALS. BIOPAK TECHNOLOGY LTD (US) 1995-09-27 EP claimed
EP-0662107-A1 DEGRADATION CONTROL OF ENVIRONMENTALLY DEGRADABLE DISPOSABLE MATERIALS BioPak Technology, Ltd. (US) 1995-07-12 EP claimed
WO-1994006866-A1 DEGRADATION CONTROL OF ENVIRONMENTALLY DEGRADABLE DISPOSABLE MATERIALS BIOPAK TECHNOLOGY, LTD. (US) 1994-03-31 WO claimed
EP-0000560-B1 PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE ALPHA-HYDROXYCARBOXYLIC ACIDS F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1982-02-03 EP claimed
US-4204044-A SELECTIVE ASYMMETRIC, ENZYMATIC DEHYDROGENATIKN USING STREPTOMYCES, PSEUDOMONAS, BACILLUS OR CORYNEFORM MICROORGANISMS HOFFMANN-LA ROCHE INC. (US) 1980-05-20 US claimed
EP-0000560-A1 Process for the preparation of optically active alpha-hydroxycarboxylic acids F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1979-02-07 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050287103-A1 Cosmetic composition comprising at least one ester and at least one film-forming polymer DAGLA, CUTA, DSG1 GPR84 2270/4885FFAR1 211/4885MAPT 2776/4885
US-20050287101-A1 Cosmetic composition comprising at least one semi-crystalline polymer, and at least one ester of dimer diol and of acid CUTA, C9, DHCR24 GPR84 1419/4885FFAR1 277/4885MAPT 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.